[Clinical practice and challenges from simple models to precise integration for serological evaluation of a non-invasive diagnosis of liver fibrosis] [0.03%]
[从简单模型到精准整合的临床实践与挑战——非侵入性诊断肝纤维化血清学评价]
R Jin,W J Ni,F J Rui et al.
R Jin et al.
Liver fibrosis is a key pathological process in the progression of chronic liver disease, and its early stage and accurate diagnosis are crucial for improving patient prognosis. In recent years, the non-invasive diagnosis of liver fibrosis ...
[Non-invasive evaluation and prediction of portal hypertension: focusing on disease progression and outcome] [0.03%]
无创性评估和预测门脉高压：着眼于疾病进展和转归
P S Xu,M C Wang,J J Chen et al.
P S Xu et al.
Portal hypertension is a major complication of cirrhosis. The current gold standard for diagnosis is the hepatic venous pressure gradient, but it possesses limitations such as invasiveness. In recent years, non-invasive tests have made sign...
[Advances and challenges in new technologies for imaging evaluation of liver fibrosis] [0.03%]
肝纤维化影像评价新技术的进展与挑战
Q C Ge,L G Lu
Q C Ge
Liver fibrosis is a common pathological process in various chronic liver diseases. Early-stage and accurate diagnosis, as well as assessment of the degree of liver fibrosis, is crucial for the management of chronic liver diseases. Conventio...
[Non-invasive assessment of liver fibrosis: prioritizing dynamic monitoring and expanding population screening] [0.03%]
肝纤维化非侵入性检测：重视动态监测和扩大人群筛查
P P Lai,S Y Chen,Y M Sun et al.
P P Lai et al.
Liver fibrosis is a common pathological process associated with multiple chronic liver diseases. Recent advancements have significantly improved the non-invasive assessment of liver fibrosis. This article focuses on the exploration of hot t...
[Research progress on clinical characteristics and pathological mechanisms of lean metabolic-associated fatty liver disease] [0.03%]
低体重代谢相关性脂肪性肝病的临床特征和病理机制研究进展
N He,X Y Zhang,B B Lyu et al.
N He et al.
The incidence rate of metabolic associated fatty liver disease (MAFLD) in our country has risen rapidly and has developed into the largest chronic liver disease with the rise of obesity and type 2 diabetes mellitus. Although obesity is clos...
[Several issues and considerations in the clinical diagnosis and treatment of immune checkpoint inhibitor-associated liver injury] [0.03%]
免疫检查点抑制剂相关肝毒性的临床诊断与治疗若干问题的思考
L Chen,D L Li
L Chen
Immune checkpoint inhibitor-associated liver injury is a special type of drug-induced liver injury, and its clinical management has already become an emerging topic in recent years. This article focuses on a series of issues that have attra...
[A case of hepatitis B surface antigen clearance achievement based on the combination of interferon and intermittent consolidation therapy] [0.03%]
基于干扰素联合间歇性巩固治疗的乙型肝炎表面抗原转阴病例报告
W Deng,S Y Wang,X Wei et al.
W Deng et al.
[A case of liver cirrhosis combined with reactive perforating collagen disease] [0.03%]
肝硬化合并反应性穿刺胶原病1例报告
X X Han,Z J Zhang,Q Y Wang
X X Han
[Study on the correlation between sarcopenia, energy metabolism, and the severity of liver disease in patients with type 2 diabetes mellitus combined with metabolic associated fatty liver disease] [0.03%]
2型糖尿病合并代谢相关性脂肪性肝病患者肌少症与能量代谢及肝脏病理严重程度的相关性研究
J Zhang,Y Li,Q Ye et al.
J Zhang et al.
Objective: To explore the demographic composition of type 2 diabetes mellitus (T2DM) with metabolic associated fatty liver disease (MAFLD) and the role of energy metabolism in the progression of MAFLD in order to provide theoretical support...
[Predictive value of a Chinese visceral adiposity index for metabolic associated fatty liver disease] [0.03%]
[中国内脏脂肪指数对代谢相关性脂肪型肝病的预测价值]
M X Zhang,L Wang,X Zhang et al.
M X Zhang et al.
Objective: To explore the correlation between Chinese visceral adiposity index (CVAI) and metabolic associated fatty liver disease (MAFLD) so as to evaluate its predictive value for MAFLD. Methods: Six hundred and thirteen cases admitted to...